BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28128512)

  • 1. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
    Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C
    BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy.
    Penner KR; Dorigo O; Aoyama C; Ostrzega N; Balzer BL; Rao J; Walsh CS; Cass I; Holschneider CH
    Gynecol Oncol; 2012 Mar; 124(3):542-8. PubMed ID: 22079678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
    Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
    Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
    Gunderson CC; Fader AN; Carson KA; Bristow RE
    Gynecol Oncol; 2012 May; 125(2):477-82. PubMed ID: 22245711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
    Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
    Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
    Baker J; Obermair A; Gebski V; Janda M
    Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.
    Shih KK; Garg K; Levine DA; Kauff ND; Abu-Rustum NR; Soslow RA; Barakat RR
    Gynecol Oncol; 2011 Oct; 123(1):88-94. PubMed ID: 21742371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer From a Population-Based Study.
    Kim SR; van der Zanden C; Ikiz H; Kuzelijevic B; Havelock J; Kwon JS
    J Obstet Gynaecol Can; 2018 Mar; 40(3):328-333. PubMed ID: 28986185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Wheeler DT; Bristow RE; Kurman RJ
    Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving response to progestin treatment of low-grade endometrial cancer.
    Baxter E; Brennan DJ; McAlpine JN; Mueller JJ; Amant F; van Gent MDJM; Huntsman DG; Coleman RL; Westin SN; Yates MS; Krakstad C; Quinn MA; Janda M; Obermair A
    Int J Gynecol Cancer; 2020 Nov; 30(11):1811-1823. PubMed ID: 32381512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
    Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
    Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
    Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
    Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
    Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
    Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of MMR in endometrial adenocarcinoma in women under 50 years old].
    Wu HX; Song JC; Shi YQ; Liu YX
    Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):733-6. PubMed ID: 23302332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.
    Ciccone MA; Whitman SA; Conturie CL; Brown N; Dancz CE; Özel B; Matsuo K
    Arch Gynecol Obstet; 2019 Mar; 299(3):801-808. PubMed ID: 30706187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.
    Pronin SM; Novikova OV; Andreeva JY; Novikova EG
    Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.